Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs

被引:326
作者
Hosokawa, Masakiyo [1 ]
机构
[1] Chiba Inst Sci, Lab Drug Metab & Biopharmaceut, Fac Pharmaceut Sci, Choshi, Chiba 2880025, Japan
关键词
carboxylesterase; CES1; CES2; prodrug metabolism; structure;
D O I
10.3390/molecules13020412
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammalian carboxylesterases (CESs) comprise a multigene family whose gene products play important roles in biotransformation of ester-or amide-type prodrugs. They are members of an alpha,beta-hydrolase-fold family and are found in various mammals. It has been suggested that CESs can be classified into five major groups denominated CES1-CES5, according to the homology of the amino acid sequence, and the majority of CESs that have been identified belong to the CES1 or CES2 family. The substrate specificities of CES1 and CES2 are significantly different. The CES1 isozyme mainly hydrolyzes a substrate with a small alcohol group and large acyl group, but its wide active pocket sometimes allows it to act on structurally distinct compounds of either a large or small alcohol moiety. In contrast, the CES2 isozyme recognizes a substrate with a large alcohol group and small acyl group, and its substrate specificity may be restricted by the capability of acyl-enzyme conjugate formation due to the presence of conformational interference in the active pocket. Since pharmacokinetic and pharmacological data for prodrugs obtained from preclinical experiments using various animals are generally used as references for human studies, it is important to clarify the biochemical properties of CES isozymes. Further experimentation for an understanding of detailed substrate specificity of prodrugs for CES isozymes and its hydrolysates will help us to design the ideal prodrugs.
引用
收藏
页码:412 / 431
页数:20
相关论文
共 98 条
[31]   Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes [J].
Hosokawa, Masakiyo ;
Furihata, Tomomi ;
Yaginuma, Yumiko ;
Yamamoto, Naoko ;
Watanabe, Natsuko ;
Tsukada, Eiko ;
Ohhata, Yoshiko ;
Kobayashi, Kaoru ;
Satoh, Testuo ;
Chiba, Kan .
DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (01) :73-84
[32]   Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes [J].
Hosokawa, Masakiyo ;
Furihata, Tomomi ;
Yaginuma, Yumiko ;
Yamamoto, Naoko ;
Koyano, Nao ;
Fujii, Ayako ;
Nagahara, Yuko ;
Satoh, Testuo ;
Chiba, Kan .
DRUG METABOLISM REVIEWS, 2007, 39 (01) :1-15
[33]  
Humerickhouse R, 2000, CANCER RES, V60, P1189
[34]   Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration [J].
Imai, T ;
Yoshigae, Y ;
Hosokawa, M ;
Chiba, K ;
Otagiri, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03) :1234-1242
[35]   Human carboxylesterase isozymes: Catalytic properties and rational drug design [J].
Imai, Teruko .
DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (03) :173-185
[36]   Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine [J].
Imai, Teruko ;
Taketani, Megumi ;
Shii, Mayumi ;
Hosokawa, Masakiyo ;
Chiba, Kan .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (10) :1734-1741
[37]   SPECIES-DIFFERENCE AND CHARACTERIZATION OF INTESTINAL ESTERASE ON THE HYDROLIZING ACTIVITY OF ESTER-TYPE DRUGS [J].
INOUE, M ;
MORIKAWA, M ;
TSUBOI, M ;
SUGIURA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1979, 29 (01) :9-16
[38]  
Kamendulis LM, 1996, J PHARMACOL EXP THER, V279, P713
[39]   In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors [J].
Kojima, A ;
Hackett, NR ;
Ohwada, A ;
Crystal, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1789-1796
[40]  
KORZA G, 1988, J BIOL CHEM, V263, P3486